CUEBS
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- Nabiximols
What it measured
Main measures
Improvement in urodynamic parameters between pre- and post-treatment evaluations: amelioration of urodynamic test will be defined as the combination of the reduction of at least 20 cmH2O in the amplitude of the maximal detrusorial contraction plus the increase of at least one third of the baseline bladder filling capacity.
Bladder, bowel and sexual function
Other measures (1)
Improvement in self-reported scales about urinary disturbances (urinary diary), in particular frequency of micturitions, episodes of diurnal and nocturnal incontinence, episodes of nocturnal micturition, micturial hesitation ; Correlation between changes in urinary disturbances evaluated by urodynamic evaluation and spasticity evaluated by Numerical Rating Scale (NRS) [15], and motor improvement e
MRI lesionsWalking and mobilityPhysical functionSpasticityBladder, bowel and sexual functionPain
Who could take part
Relapsing MS
Inclusion: - Patients who will start therapy with Sativex according to the judgment of the physician, and who are eligible to the treatment following AIFA guidelines Exclusion: - Male patients affected by benign prostatic hypertrophy
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
To assess the possible improvement of urinary dysfunction using the urodynamic evaluation in MS patients affected by urinary disturbances and eligible to the treatment with Sativex
Loading reviews and guidelines…
Related trials
- Efficacy and Safety Evaluation of Nabilone as Adjunctive …
Phase 4 · Completed
No result found
History
Started
Jun 2021
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error